ClinicalTrials.gov
public full text
Public Domain
An Observational Study of Epoetin Beta (NeoRecormon) in Participants With Cancer Receiving Chemotherapy
This observational study will evaluate the efficacy and safety of epoetin beta (NeoRecormon) in participants with symptomatic anemia and cancer receiving chemotherapy. Participants receiving NeoRecormon once weekly in accordance with the Summary of Product Characteristics will be followed for 4 months.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Epoetin Beta in Patients Undergoing Chemotherapy for Solid Tumors#980461
- Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma#904803
- Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2)#813365
- Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)#862496
- Remote Physical Activity Programming to Improve Outcomes in Cancer Survivors With and Without Type 2 Diabetes#905149
Record · ID 860402
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive